Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review

Hossen, Sarwar; Hossain, M. Khalid; Basher, Mohammad Khairul; Mia, M.N.H.; Rahman, Mehbuba; Uddin, M. Jalal

doi:10.1016/j.jare.2018.06.005

Cited by 696 publications

(377 citation statements)

References 299 publications

Supporting

Mentioning

373

Contrasting

Unclassified

Order By: Relevance

“…25,26 Actually, the nanocarrier is more preferable than traditional formulation in improving the efficacy of topical therapeutic, minimizing the side-effects of prolonged use and reducing dose of administration. 29 We developed a topical preparation based on liposomemediated transdermal delivery of miR-210 antisense to overcome the limitation of penetration skin barriers and improve the specific penetration without unwanted effects on skin. 29 We developed a topical preparation based on liposomemediated transdermal delivery of miR-210 antisense to overcome the limitation of penetration skin barriers and improve the specific penetration without unwanted effects on skin.…”

Section: Discussionmentioning

confidence: 99%

“…27,28 Liposome is one of the most reported nanocarriers, which is a naturally occurring phospholipid-based amphipathic nanocarrier. 29 We developed a topical preparation based on liposomemediated transdermal delivery of miR-210 antisense to overcome the limitation of penetration skin barriers and improve the specific penetration without unwanted effects on skin. Then, we applied this topical drug, NG-anti-miR-210, in the IMQ-induced psoriasis-like mouse model and confirmed that NG-anti-miR-210 exhibited equal therapeutic effect on psoriasis-like inflammation but was safer and more convenient compared with i.d.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice

Feng

Zhang

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic, recurrent inflammatory autoimmune skin disease. Although its etiology and pathogenesis are complex and multifarious, it has been proved to be closely related to dysregulation of immune cell function as well as keratinocyte proliferation/differentiation. Our previous study demonstrated that miRNA-210 (miR-210) plays an important role in the formation of skin lesions and immune imbalance in psoriasis. Here, we developed a biomimetic reconstituted high-density lipoprotein (rHDL) nanocarrier gel containing miR-210 antisense (NG-anti-miR-210) to investigate its effect on imiquimod (IMQ)-induced psoriasis-like dermatitis in mice. We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4 + T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice. In addition, the proportion of T-helper (Th)1 and Th17 cells in dermal and splenic cells of IMQ-treated mice were decreased by application of NG-anti-miR-210, accompanied by decreased interleukin-17A and c-interferon mRNA levels. Therefore, our data demonstrate that topical inhibition of miR-210 delivered by rHDL nanocarrier effectively alleviates the psoriasis-like inflammation in mice and provides a potentially effective topical drug for psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice

Feng

Zhang

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Moreover, nanocarrier can be synthesized from polymers that are able to respond to specific stimuli based on physiochemical differences between cancer and non-cancerous cells, leading to the development of smart drug delivery systems [45]. Their aim is to reduce dosage frequency in a spatially controlled manner and facilitate the delivery and accumulation of the therapeutic system to the target tumor tissue.…”

Section: Nanocarriers For Gene Therapy and Smart Delivery Systemsmentioning

confidence: 99%

“…Their aim is to reduce dosage frequency in a spatially controlled manner and facilitate the delivery and accumulation of the therapeutic system to the target tumor tissue. Followed by the release of anticancer agent at the specific location at a precise concentration based on internal or external stimuli [45]. Smart polymer nanocarriers can respond to stimuli such as changes in pH, enzyme configurations, redox reactions and light [45].…”

Section: Nanocarriers For Gene Therapy and Smart Delivery Systemsmentioning

confidence: 99%

The Principles behind Targeted Therapy for Cancer Treatment

Albusairi¹,

Khajah²

2020

Tumor Progression and Metastasis

View full text Add to dashboard Cite

The advent of molecular and genetic advancement in the field of oncology research has led to a shift in the treatment of various forms of cancer from traditional chemotherapeutics to targeted therapy. The principle behind targeted therapy is utilizing therapeutics designed to interfere with specific molecules that have a relatively specific or higher expression profile in cancer cells and are critical for cancer growth and progression. These were designed as mechanistic therapeutics in the form of small molecules and monoclonal antibodies. Currently, they have been modified to incorporate passive or active targeting delivery systems to improve their specific distribution and enhance cytotoxicity towards cancer cells while simultaneously reducing their systemic toxicity profile. Passive targeting employs encapsulated delivery systems to take advantage of the enhanced permeation and retention effect of the tumor microenvironment, while active targeting relies on receptor mediated interactions, such as cell surface ligands conjugated to the therapeutic moiety. A synergistic strategy for cancer therapy is evolving, where precision medicine acts as a diagnostic prerequisite for targeted therapy via prognostic biomarkers and tumor genotyping. Despite the plethora of research undertaken in targeted therapy, limited numbers were approved for clinical use, and significant challenges remain to be addressed.

show abstract

“…Using nanocarriersf or drug delivery has been considered to be effective in suppressing negative systematic side effects of the distributed drugs, while retaining their therapeutic effects. [6,7] Several nanocarriersb ased on variousm aterials have been reported in literature for delivery of ATO. These include polylactic acid/magnetic hybrid nanoparticles, polyacrylic acid cappedm esoporous silica nanoparticles (MSNs) and magnetite dopedm esoporous silica nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

Zeolitic Imidazolate Framework‐8 as pH‐Sensitive Nanocarrier for “Arsenic Trioxide” Drug Delivery

Ettlinger

Moreno

Volkmer

et al. 2019

Chemistry A European J

View full text Add to dashboard Cite

Previous resultsr evealed that arsenic trioxide might be used as promising therapeutic agent for the treatment of some solid tumoursa sa typical teratoid rhabdoid tumours (ATRT). However,i no rder to becomea na pproved drug for solid tumour treatment, the active formulation has to get more efficient and feasible-buta tt he same time less toxic. One of the possibilities to achieve this dichotomy is to use nanomedicine tools. Herein, we report on the Znbased metal-organicf ramework ZIF-8 (Zeolitic Imidazolate Framework-8) which turned out to be ap romising candidate for the delivery of As III species. It conjointly features ah igh drug loading capacity and ap rominent pH-triggered release behaviour.A s III -loaded ZIF-8 nanoparticlesc oated and noncoatedw ith polyethylene glycol weres tudied by XRPD, IR, Raman, TGA, TEM, EDX, CHN-elemental analysis, sorption analysisa nd ICP-OES, and their cytotoxicity was evaluated in vitro.

show abstract

Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review

Abstract: Graphical abstract

Cited by 696 publications

References 299 publications

Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice

Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice

The Principles behind Targeted Therapy for Cancer Treatment

Zeolitic Imidazolate Framework‐8 as pH‐Sensitive Nanocarrier for “Arsenic Trioxide” Drug Delivery

Contact Info

Product

Resources

About